These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24781541)

  • 1. Trial watch: personalized medicines in late-stage development.
    Milne CP; Garafalo S; Bryan C; McKiernan M
    Nat Rev Drug Discov; 2014 May; 13(5):324-5. PubMed ID: 24781541
    [No Abstract]   [Full Text] [Related]  

  • 2. Marc Kirschner. Interview by Asher Mullard.
    Kirschner M
    Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982
    [No Abstract]   [Full Text] [Related]  

  • 3. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
    Chackalamannil S; Desai MC
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: The Innovative Medicines Initiative--collaborations are key to innovating R&D processes.
    Laverty H; Goldman M
    Biotechnol J; 2014 Sep; 9(9):1095-6. PubMed ID: 25174501
    [No Abstract]   [Full Text] [Related]  

  • 5. [PHARMACEUTICAL INDUSTRY AND PERSONALIZED MEDICINE: A PARADIGM SHIFT IN THE DEVELOPMENT OF NEW DRUGS].
    Scheen AJ
    Rev Med Liege; 2015; 70(5-6):237-41. PubMed ID: 26285445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial watch: Clinical trial cycle times continue to increase despite industry efforts.
    Martin L; Hutchens M; Hawkins C
    Nat Rev Drug Discov; 2017 Mar; 16(3):157. PubMed ID: 28184041
    [No Abstract]   [Full Text] [Related]  

  • 7. Network medicine: finding the links to personalized therapy.
    Chen JY; Piquette-Miller M; Smith BP
    Clin Pharmacol Ther; 2013 Dec; 94(6):613-6. PubMed ID: 24241633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2011 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
    [No Abstract]   [Full Text] [Related]  

  • 9. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.
    Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A
    Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing pharmacogenetic evidence throughout clinical development.
    Burns DK
    Clin Pharmacol Ther; 2010 Dec; 88(6):867-70. PubMed ID: 20981004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving from an asthma pipe dream to a pipeline.
    Holmes D
    Nat Rev Drug Discov; 2012 Oct; 11(10):737-8. PubMed ID: 23023668
    [No Abstract]   [Full Text] [Related]  

  • 12. Toward personalized medicine in the neuropsychiatric field.
    Wong EH; Fox JC; Ng MY; Lee CM
    Int Rev Neurobiol; 2011; 101():329-49. PubMed ID: 22050858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Know your target, know your molecule.
    Bunnage ME; Gilbert AM; Jones LH; Hett EC
    Nat Chem Biol; 2015 Jun; 11(6):368-72. PubMed ID: 25978985
    [No Abstract]   [Full Text] [Related]  

  • 14. Vas Narasimhan.
    Narasimhan V; Mullard A
    Nat Rev Drug Discov; 2016 Jan; 15(1):10-1. PubMed ID: 26718275
    [No Abstract]   [Full Text] [Related]  

  • 15. Early phase clinical trials in pediatric hematology and oncology.
    Corbacioglu S
    Klin Padiatr; 2012 Apr; 224(3):197-200. PubMed ID: 22511313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An industrial perspective on contemporary applications of PBPK models in drug discovery and development.
    Smith BJ
    Biopharm Drug Dispos; 2012 Mar; 33(2):53-4. PubMed ID: 22407480
    [No Abstract]   [Full Text] [Related]  

  • 17. Virtual drug discovery with the rise of Chinese CROs.
    Zhang MQ
    Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343
    [No Abstract]   [Full Text] [Related]  

  • 18. Market watch: industry perspectives on personalized medicine.
    Zuckerman R; Milne CP
    Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258
    [No Abstract]   [Full Text] [Related]  

  • 19. Could pharma open its drug freezers?
    Mullard A
    Nat Rev Drug Discov; 2011 Jun; 10(6):399-400. PubMed ID: 21629278
    [No Abstract]   [Full Text] [Related]  

  • 20. The risky business of drug development in neurology.
    Craven R
    Lancet Neurol; 2011 Feb; 10(2):116-7. PubMed ID: 21256451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.